Analyst Price Target is $58.78
▲ +52.79% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Xenon Pharmaceuticals in the last 3 months. The average price target is $58.78, with a high forecast of $65.00 and a low forecast of $49.00. The average price target represents a 52.79% upside from the last price of $38.47.
Current Consensus is
Buy
The current consensus among 10 investment analysts is to buy stock in Xenon Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More
